NeuroSense Therapeutics Ltd. - Ordinary Shares (NQ:NRSN)

0.8804 +0.0273 (+3.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2026 Add to My Watchlist

Price and Volume

Volume	96,598
Open	0.9300
Bid (Size)	0.8732 (100)
Ask (Size)	0.9200 (2,200)
Prev. Close	0.8531
Today's Range	0.8602 - 0.9300
52wk Range	0.6801 - 2.600
Shares Outstanding	23,228,941
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Beyond AI: How Non-AI Tech Innovations are Fueling a New Era of Stock Market Growth

December 11, 2025

As 2025 draws to a close, a powerful undercurrent of technological innovation, extending far beyond the pervasive influence of artificial intelligence, is demonstrably reshaping the global stock...

Via MarketMinute

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 11, 2025

Via Benzinga

Performance

YTD	+12.9%	+12.9%
1 Month	-13.7%	-13.7%
3 Month	-19.2%	-19.2%
6 Month	-25.2%	-25.2%
1 Year	-23.4%	-23.4%

More News

Wednesday's session: top gainers and losers ↗

September 10, 2025

Via Chartmill

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

August 01, 2025

Via Chartmill

These stocks are moving in today's session ↗

August 01, 2025

Via Chartmill

The market is filled with gapping stocks in Friday's session. ↗

August 01, 2025

Via Chartmill

NeuroSense Inches Closer to Pharma Partnership as Canadian Regulatory Progress Turns Heads

June 26, 2025

Via News Direct

Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights ↗

May 12, 2025

Via Benzinga

This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday ↗

May 12, 2025

Via Benzinga

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

April 24, 2025

Via News Direct

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 20, 2025

From Market News Alerts

Via Business Wire

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

March 19, 2025

Via News Direct

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

March 17, 2025

From PESG Research

Via Business Wire

EXCLUSIVE: Nano-Cap NeuroSense Schedules FDA Meeting To Advance Lead Program And Marketing Application Submission ↗

October 28, 2024

Via Benzinga

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

October 17, 2024

Via News Direct

EXCLUSIVE: NeuroSense Therapeutics In Advanced Talks With Several Multi-Billion-Dollar Pharma Companies To Partner Its Lead Drug ↗

August 28, 2024

Via Benzinga

NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 ↗

June 24, 2024

Via InvestorPlace

NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 ↗

April 05, 2024

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

March 15, 2024

Via InvestorPlace

NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 ↗

January 29, 2024

Via Benzinga

Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 06, 2023

Via Benzinga

US Stocks Higher; Private Payrolls Rise By 103,000 In November ↗

December 06, 2023

Via Benzinga

Why SentinelOne Shares Are Trading Higher By Over 18%; Here Are 20 Stocks Moving Premarket ↗

December 06, 2023

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

December 06, 2023

Via InvestorPlace

Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

December 05, 2023

Via Benzinga

Frequently Asked Questions

Is NeuroSense Therapeutics Ltd. - Ordinary Shares publicly traded?

Yes, NeuroSense Therapeutics Ltd. - Ordinary Shares is publicly traded.

What exchange does NeuroSense Therapeutics Ltd. - Ordinary Shares trade on?

NeuroSense Therapeutics Ltd. - Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares?

The ticker symbol for NeuroSense Therapeutics Ltd. - Ordinary Shares is NRSN on the Nasdaq Stock Market

What is the current price of NeuroSense Therapeutics Ltd. - Ordinary Shares?

The current price of NeuroSense Therapeutics Ltd. - Ordinary Shares is 0.8804

When was NeuroSense Therapeutics Ltd. - Ordinary Shares last traded?

The last trade of NeuroSense Therapeutics Ltd. - Ordinary Shares was at 02/19/26 04:00 PM ET

What is the market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares?

The market capitalization of NeuroSense Therapeutics Ltd. - Ordinary Shares is 20.45M

How many shares of NeuroSense Therapeutics Ltd. - Ordinary Shares are outstanding?

NeuroSense Therapeutics Ltd. - Ordinary Shares has 20M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.